Physician profile
Maria E Vanadia
NPI 1861247603
$3,196.91
in general payments reported to CMS, 2019-2025
16 companies · $1,890 in 2025
The $1,890 reported for 2025 was more than what 90% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,307 · 2025: $1,890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,938 · Education: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,937.58 |
| Education | $259.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,216.05 | 2024-2025 | |
| Incyte Corporation | $317.94 | 2024-2025 | Opzelura |
| Galderma Laboratories, L.P. | $262.53 | 2024-2025 | Nemluvio, Aklief, Oracea |
| Janssen Biotech, INC. | $174.93 | 2025 | Tremfya |
| Genzyme Corporation | $169.27 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $165.89 | 2025 | Dupixent |
| Lilly USA, LLC | $141.88 | 2024-2025 | Taltz, Ebglyss, Zepbound |
| Amgen INC. | $138.69 | 2024-2025 | Otezla |
| Ucb, INC. | $137.19 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $117.96 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $113.87 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $109.04 | 2024-2025 | Sotyktu |
| Organon LLC | $82.34 | 2025 | Vtama |
| Helsinn Therapeutics (U.S.), INC. | $17.17 | 2025 | Valchlor |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.08 | 2025 | Arazlo |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $16.08 | 2025 | Watchman Access System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Vanadia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.